Comparable stake leader
Charles Cherington
SEC ownership of Ernexa Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000748592.
Disclosed value leader
Charles Cherington
Comparable rows
24/50
Latest evidence
31 Mar 2026
- Symbol
- ERNA, ERNAW on Nasdaq
- SEC evidence covered
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- Charles Cherington
- Latest 13D/G holder
- Charles Cherington
- Latest parsed evidence date
- 31 Mar 2026
- CIK
- 0000748592
- Location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Who this page is about.
2 identity fields
Ownership snapshot
Top shareholders of Ernexa Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Charles Cherington
Disclosed value leader
Charles Cherington
Comparable rows
24/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 35%
26 rows are not safely comparable across share classes.
13D/G row: Charles Cherington
Showing 1-8 of 50 holder rows.
Quick read
Charles Cherington leads the comparable SEC ownership view at 35%.
24 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Charles Cherington's linked filing trail.
Comparable ownership
Top 5
Charles Cherington
35%
Freebird Partners LP
9.9%
Shameek Konar
9.7%
Bleichroeder LP
6.9%
John D. Halpern
5.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Charles Cherington |
13D/G
3/4/5
10%+ Owner
|
35%
|
$12,949,602
10,791,335 shares
|
$0 | 10 Feb 2026 |
| Freebird Partners LP |
3/4/5
13D/G
10%+ Owner
|
9.9%
from 13D/G
|
$1,503,337
2,774,627 shares
mixed-class rows
|
— | 14 Dec 2023 |
| Shameek Konar |
13D/G
|
9.7%
|
$21,302
118,342 shares
|
-$597,053 | 10 Feb 2026 |
| Bleichroeder LP |
13F
13D/G
Company
|
6.9%
from 13D/G
|
$454,000
4,000,000 shares
mixed-class rows
|
— | 31 Mar 2026 |
| John D. Halpern |
3/4/5
13D/G
10%+ Owner
|
5.6%
from 13D/G
|
$1,118,891
1,123,006 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Nicholas J. Singer |
3/4/5
13D/G
Director · Nicholas Jason Singer
|
4.9%
from 13D/G
|
$962,330
954,608 shares
mixed-class rows
|
— | 02 Dec 2022 |
| IAF, LLC |
13D/G
|
4.1%
|
$584,191
315,779 shares
|
$0 | 28 Jul 2025 |
| Dauntless Investment Group, LLC |
13F
Company
|
50%
|
$121,876
612,443 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$4,221,826.
Buys
$4,221,826
Insiders: 1
Sells
$0
Insiders: 0
Net
+$4,221,826
Shares: +25,241,163
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 25,241,163
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 4,000,000 | 0 | $2,000,000 | $0 | +$2,000,000 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 21,241,163 | 0 | $2,221,826 | $0 | +$2,221,826 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to Ernexa Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Charles Cherington
Net 12M change
+$4,221,826
Latest report
10 Feb 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Charles Cherington | 10%+ Owner | $3,389,720 | +$4,221,826 | +125% | Filing P/S | 10 Feb 2026 |
| Freebird Partners LP | 10%+ Owner | $1,503,337 | Filing P/S | 14 Dec 2023 | ||
| George P. Denny III | 10%+ Owner | $1,134,456 | Mixed | 02 Dec 2022 | ||
| John D. Halpern | 10%+ Owner | $1,118,891 | Mixed | 02 Dec 2022 | ||
| Nicholas J. Singer | Director | $962,330 | Mixed | 02 Dec 2022 | ||
| Roger Sidhu | Chief Medical Officer | $200,012 | Mixed | 20 Sep 2022 | ||
| Kevin Damour | Chief Scientific Officer | $159,248 | Mixed | 28 Jun 2022 | ||
| Sandra M. Gurrola | Sr. VP of Finance | $1,103 | Mixed | 21 Jun 2025 | ||
| Andrew C. Jackson | Chief Financial Officer | Mixed | 03 Jun 2022 | |||
| Erich Mohr | Director | Mixed | 08 Dec 2021 | |||
| Howard J. Federoff | CEO & President, Director | Mixed | 11 Mar 2022 | |||
| Erin S. Enright | Director | Mixed | 14 Jan 2022 | |||
| Jay Sial | Chief Administration Officer | Mixed | 11 Mar 2022 | |||
| Luba Greenwood | Director | Mixed | 08 Dec 2021 | |||
| Heather B. Redman | Director | Mixed | 14 Jan 2022 | |||
| Gregory Fiore | Director | Mixed | 01 Aug 2022 | |||
| Dennis Langer | Director | Mixed | 08 Dec 2021 | |||
| William A. Wexler | Director | Mixed | 07 Feb 2025 | |||
| Matthew Angel | President and CEO, Director | Mixed | 12 Jan 2023 | |||
| Elena Ratner | Director | Mixed | 13 Jan 2025 |
Recent insider transactions for Ernexa Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles Cherington | ERNA | Common Stock | Purchase | 143.9% | $2,000,000 | $0.5000 | 4,000,000 | 6,779,440 | 10 Feb 2026 | Direct |
| Charles Cherington | ERNA | Warrants to Purchase Common Stock | Purchase | 4,000,000 | 4,000,000 | 10 Feb 2026 | Direct | |||
| Sandra M. Gurrola | ERNA | Common Stock | Options Exercise | 37.5% | 30 | 110 | 21 Jun 2025 | Direct | ||
| Sandra M. Gurrola | ERNA | Restricted Stock Units | Options Exercise | 30 | 0 | 21 Jun 2025 | Direct | |||
| Charles Cherington | ERNA | Common Stock | Purchase | 104% | $2,221,826 | $0.1046 | 21,241,163 | 41,659,743 | 09 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.